IP Verse

Diagnostic Methods For T Cell Therapy - EP3302507

The patent EP3302507 was granted to Kite Pharma on Feb 22, 2023. The application was originally filed on May 27, 2016 under application number EP16800846A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3302507

KITE PHARMA
Application Number
EP16800846A
Filing Date
May 27, 2016
Status
Granted And Under Opposition
Jan 20, 2023
Grant Date
Feb 22, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANTNov 22, 2023BOULT WADE TENNANTADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2002006409
DESCRIPTIONUS2014154228
DESCRIPTIONUS5728388
DESCRIPTIONWO2008081035
INTERNATIONAL-SEARCH-REPORTUS2013195800
INTERNATIONAL-SEARCH-REPORTUS2014377334
INTERNATIONAL-SEARCH-REPORTWO2013169386
INTERNATIONAL-SEARCH-REPORTWO2015069770
OTHERUS2018344767
SEARCHWO2016191756

Non-Patent Literature (NPL) Citations (32) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- HUANG HUI et al., Cell Immunol., (20020000), vol. 217, no. 1-2, pages 12 - 22-
DESCRIPTION- ROSENBERG, S.A.KOCHENDERFER, J.N., Mol Ther., (20110000), vol. 19, no. 11, pages 1928 - 1930-
EXAMINATION- DUDLEY MARK E ET AL, "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, (20081110), vol. 26, no. 32, doi:10.1200/JCO.2008.16.5449, ISSN 0732-183X, pages 5233 - 5239, XP009117624
EXAMINATION- Melenhorst J. J. ET AL, "Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation", Haematologica, IT, (20111201), vol. 97, no. 6, doi:10.3324/haematol.2011.053363, ISSN 0390-6078, pages 867 - 873, XP055776007
INTERNATIONAL-SEARCH-REPORT- DEHQANZADA et al., "Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology", Oncol Rep., (20070301), vol. 17, pages 687 - 694, XP009112817 [Y] 10 * . entire ducument *-
OPPOSITION- Anonymous, "CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma; History of Changes for Study: NCT00924326", ClinicalTrials.gov; NCT00924326, (20150516), ClinicalTrials.gov; NCT00924326 , URL: https://classic.clinicaltrials.gov/ct2/history/NCT00924326, (20240322), XP093144583-
OPPOSITION- Bot Adrian; Rossi John M; Jiang Yizhou; Navale Lynn; Shen Yueh-wei; Sherman Marika; Mardiros Armen; Yoder Sean C; Go William Y; Rosenberg Steven A; Wiezorek Jeff; Chang David D; Kochenderfer James N; Roberts Margo R Kite Pharma, Santa Monica, CA USA, "Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy", Blood, American Society of Hematology, US, US , (20151130), vol. 126, no. 23, ISSN 0006-4971, page 4426, XP009509578-
OPPOSITION- Kalos Michael, Levine Bruce L, Porter David L, Katz Sharyn, Grupp Han A, Bagg Adam, June Carl H, "Supplementary Materials for T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients ,with Advanced Leukemia", Science translation Medicine, (20110810), pages 1 - 25, XP093134695-
OPPOSITION- Kochenderfer James N, "Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-IS levels", ClinicalTrials, (20170601), pages 1 - 29, XP093182454-
OPPOSITION- Enrico Proietti; Federica Moschella; Imerio Capone; Filippo Belardelli;, "Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy", Molecular Oncology, Elsevier, (20111111), vol. 6, no. 1, doi:10.1016/j.molonc.2011.11.005, ISSN 1574-7891, pages 1 - 14, XP028452884
OPPOSITION- Steven A Rosenberg, James N Kochenderfer, "Personalized Cell Transfer Immunotherapy for B-Cell Malignancies and Solid Cancers", Molecular Therapy, Elsevier Inc., US, US , (20111101), vol. 19, no. 11, doi:10.1038/mt.2011.223, ISSN 1525-0016, pages 1928 - 1930, XP055259350
OPPOSITION- David L. Porter, Bruce L. Levine, Michael Kalos, Adam Bagg, Carl H. June, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", The New England journal of medicine, Massachusetts Medical Society, US, US , (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP002732435
OPPOSITION- Luca Gattinoni, Finkelstein Steven E., Klebanoff Christopher A., Antony Paul A., Palmer Douglas C., Spiess Paul J., Hwang Leroy N., Yu Zhiya, Wrzesinski Claudia, Heimann David M., Surh Charles D., Rosenberg Steven A., Restifo Nicholas P., "Removal of homeostatic cytokine sinks by lymphodepletion enhances D17 the efficacy of adoptively transferred tumor-specific CD 8+ T cells", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20051003), vol. 202, no. 7, doi:10.1084/jem.20050732, ISSN 0022-1007, pages 907 - 912, XP055606260
OPPOSITION- Michael Kalos et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Science Translational Medicine, (20110810), vol. 3, doi:10.1126/scitranslmed.3002842, page 95, XP002667262
OPPOSITION- Ding Zhi-Chun, Zhou Gang, "Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects", CLINICAL & DEVELOPMENTAL IMMUNOLOGY, Hindawi Publishing Corp, US, US , (20120101), vol. 2012, doi:10.1155/2012/890178, ISSN 1740-2522, pages 1 - 12, XP093144573
OPPOSITION- Moschella Federica, Torelli Giovanni Fernando, Valentini Mara, Urbani Francesca, Buccione Carla, Petrucci Maria Teresa, Natalino Fiammetta, Belardelli Filippo, Foà Robin, Proietti Enrico, "Cyclophosphamide Induces a Type I Interferon-Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy", Clinical Cancer Research, Association for Cancer Research, US, US, (20130801), vol. 19, no. 15, doi:10.1158/1078-0432.CCR-12-3666, ISSN 1078-0432, pages 4249 - 4261, XP093144574
OPPOSITION- R. J. Brentjens, I. Riviere, J. H. Park, M. L. Davila, X. Wang, J. Stefanski, C. Taylor, R. Yeh, S. Bartido, O. Borquez-Ojeda, M. Olszewska, Y. Bernal, H. Pegram, M. Przybylowski, D. Hollyman, Y. Usachenko, D. Pirraglia, J. Hosey, E. Santos, E. Halton, P. Maslak, D. Scheinberg, J. Jurcic, M. Heaney, G. Heller, M. Frattini, M. Sadelain, "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias", Blood, (20111103), vol. 118, no. 18, doi:10.1182/blood-2011-04-348540, ISSN 00064971, pages 4817 - 4828, XP055169039
OPPOSITION- Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay, Jenna M. Voutsinas, Qian Wu, Ted Gooley, Daniel Li, Sindhu Cherian, Xueyan Chen, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Utkarsh H. Acharya, Ryan D. Cassaday, Aude G. Chapuis, Tejaswini M. Dhawale, Paul C. Hendrie, Hans-Peter Kiem, Ryan C. Lynch, Jorge Ramos, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle, "The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells", Blood, American Society of Hematology, US, US , (20190425), vol. 133, no. 17, doi:10.1182/blood-2018-11-887067, ISSN 0006-4971, pages 1876 - 1887, XP055626703
OPPOSITION- Zeng Fanyuan, Zhang Hanwen, Wang Shuhua, Passang Tenzin, Li Yiwen Helen, Funk Christopher Ronald, Wyman Sarah, O'leary Colin B, Abousaud Aseala I, Liu Yuan, Dhodapkar Kavita, Waller Edmund K., Koff Jean L., "Early Plasma Levels of IL7 and IL15 Predict Response to Chimeric Antigen Receptor T Cell Therapy (CAR-T) in Large B-Cell Lymphoma (LBCL) Patients", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20231102), vol. 142, no. Supplement 1, doi:10.1182/blood-2023-189248, ISSN 0006-4971, pages 6112 - 6114, XP093278557
OPPOSITION- Dudley Mark E; Yang James C; Sherry Richard; Hughes Marybeth S; Royal Richard; Kammula Udai; Robbins Paul F; Huang JianPing; Citrin Deborah E; Leitman Susan F; Wunderlich John; Restifo Nicholas P; Thomasian Armen; Downey Stephanie G; Smith Franz O; Klapper Jacob; Morton Kathleen; Laurencot Carolyn; White Donald E; Rosenberg Steven A, "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20081110), vol. 26, no. 32, doi:10.1200/JCO.2008.16.5449, ISSN 0732-183X, pages 5233 - 5239, XP009117624
OPPOSITION- James N. Kochenderfer, Robert P.T. Somerville, Tangying Lu, Victoria Shi, Adrian Bot, John Rossi, Allen Xue, Stephanie L. Goff, James C. Yang, Richard M. Sherry, Christopher A. Klebanoff, Udai S. Kammula, Marika Sherman, Arianne Perez, Constance M. Yuan, Tatyana Feldman, Jonathan W. Friedberg, Mark J. Roschewski, Steven A. Feldman, Lori Mcintyre, Mary Ann Toomey, Steven A. Rosenberg, "Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels", Journal of Clinical Oncology, Grune & Stratton, (20170314), vol. 35, no. 16, doi:10.1200/JCO.2016.71.3024, ISSN 0732-183X, pages 1803 - 1813, XP055488634
OTHER- THIANT et al., "Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD", Bone Marrow Transplantation, (20110000), vol. 46, pages 1374 - 1381, XP055899587
OTHER- GATTINONI et al., "Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells", JEM, (20050000), vol. 202, no. 7, doi:10.1084/jem.20050732, pages 907 - 912, XP055606260
OTHER- DUDLEY et al., "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens", J Clin Oncol, (20080000), vol. 26, no. 32, doi:10.1200/JCO.2008.16.5449, pages 5233 - 5239, XP009117624
OTHER- MELENHORST et al., "Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation", Haematologica, (20120000), vol. 97, no. 6, pages 867 - 873, XP055776007
SEARCH- BOT ADRIAN ET AL, "Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20151130), vol. 126, no. 23, ISSN 0006-4971, page 4426, XP009509578 [PX] 1-20 * abstract *-
SEARCH- HUANG HUI ET AL, "Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors.", CELLULAR IMMUNOLOGY, (200205), vol. 217, no. 1-2, ISSN 0008-8749, pages 12 - 22, XP002786801 [Y] 1-20 * abstract *-
SEARCH- PEREZ ARIANNE ET AL, "Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20151130), vol. 126, no. 23, ISSN 0006-4971, XP009509580 [PX] 1-20 * abstract *-
SEARCH- ROSSI JOHN M ET AL, "Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20151130), vol. 126, no. 23, ISSN 0006-4971, XP009509579 [PX] 1-20 * abstract *-
SEARCH- STEVEN A ROSENBERG ET AL, "Personalized Cell Transfer Immunotherapy for B-Cell Malignancies and Solid Cancers", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, US, (20111101), vol. 19, no. 11, doi:10.1038/mt.2011.223, ISSN 1525-0016, pages 1928 - 1930, XP055259350 [I] 1-20 * page 1928, column 1, paragraph 2 * * page 1929, column 2, paragraph 3 - column 3, paragraph 1 * [Y] 1-20
SEARCH- J. N. KOCHENDERFER ET AL, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", BLOOD, (20111208), vol. 119, no. 12, doi:10.1182/blood-2011-10-384388, ISSN 0006-4971, pages 2709 - 2720, XP055145503 [A] 1-20 * abstract *
SEARCH- J. N. KOCHENDERFER ET AL, "Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor", JOURNAL OF CLINICAL ONCOLOGY, (20140825), vol. 33, no. 6, doi:10.1200/JCO.2014.56.2025, ISSN 0732-183X, pages 540 - 549, XP055193969 [A] 1-20 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents